A New Drug Application (NDA) is the FDA submission seeking approval to market a new drug in the United States.
NDAs include clinical study reports, statistical analyses, and CMC data demonstrating safety and efficacy. All supporting data originate from IRB-approved trials conducted under Good Clinical Practice. FDA review assesses benefitñrisk balance and labeling accuracy. A well-prepared NDA supports efficient regulatory review and successful product launch.